AKT1 and lobular neoplasia: Based on this, PCPH may target the PI3K/AKT/NF-κB pathway to regulate amino acid metabolic disorders and interrupt the vicious cycle of inflammation and metabolism, thereby exerting multi-dimensional therapeutic effects on LN.